Beraprost

Jump to: navigation, search
Beraprost
Beraprost svg.png
Clinical data
Routes of
administration
Oral
ATC code
Legal status
Legal status
  •  ?
Pharmacokinetic data
Bioavailability50–70%
MetabolismUnknown
Elimination half-life35–40 minutes
Excretion?
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC24H30O5
Molar mass398.492 g/mol

WikiDoc Resources for Beraprost

Articles

Most recent articles on Beraprost

Most cited articles on Beraprost

Review articles on Beraprost

Articles on Beraprost in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Beraprost

Images of Beraprost

Photos of Beraprost

Podcasts & MP3s on Beraprost

Videos on Beraprost

Evidence Based Medicine

Cochrane Collaboration on Beraprost

Bandolier on Beraprost

TRIP on Beraprost

Clinical Trials

Ongoing Trials on Beraprost at Clinical Trials.gov

Trial results on Beraprost

Clinical Trials on Beraprost at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Beraprost

NICE Guidance on Beraprost

NHS PRODIGY Guidance

FDA on Beraprost

CDC on Beraprost

Books

Books on Beraprost

News

Beraprost in the news

Be alerted to news on Beraprost

News trends on Beraprost

Commentary

Blogs on Beraprost

Definitions

Definitions of Beraprost

Patient Resources / Community

Patient resources on Beraprost

Discussion groups on Beraprost

Patient Handouts on Beraprost

Directions to Hospitals Treating Beraprost

Risk calculators and risk factors for Beraprost

Healthcare Provider Resources

Symptoms of Beraprost

Causes & Risk Factors for Beraprost

Diagnostic studies for Beraprost

Treatment of Beraprost

Continuing Medical Education (CME)

CME Programs on Beraprost

International

Beraprost en Espanol

Beraprost en Francais

Business

Beraprost in the Marketplace

Patents on Beraprost

Experimental / Informatics

List of terms related to Beraprost

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.

Clinical Pharmacology

As an analogue of prostacyclin PGI2, beraprost effects vasodilation, which in turn lowers the blood pressure. Beraprost also inhibits platelet aggregation, though the role this phenomenon may play in relation to pulmonary hypertension has yet to be determined.

Dosage and administration

Beraprost is administered orally as a pill.

References


Linked-in.jpg